Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ocular Therapeut
(NQ:
OCUL
)
6.290
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ocular Therapeut
< Previous
1
2
Next >
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
October 11, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations
September 28, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors
September 22, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts
September 13, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference
August 10, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
August 09, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
August 05, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration
July 29, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results
July 28, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
July 23, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million
July 22, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration
June 29, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
May 26, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update
May 05, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 03, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant
May 03, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 29, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report First Quarter 2021 Financial Results
April 28, 2021
From
Ocular Therapeutix, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.